Cantor Fitzgerald analyst Louise Chen initiated coverage of Oncolytics with an Overweight rating and C$9 price target. The potential for Oncolytics’ clinical candidate, pelareorep, to boost the effectiveness of chemotherapy and a range of immunotherapies, with an immediate focus on checkpoint inhibitors, across multiple cancer indications is underappreciated, the analyst tells investors in a research note. The firm thinks pipeline advancements should drive earnings-estimate revisions and the stock higher.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONCY:
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
- Oncolytics reports Q4 EPS (C$0.14) vs. (C$0.14) last year
- Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
